Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02628535 · ClinicalTrials.gov registry record · Phase 1
Safety Study of MGD009 in B7-H3-expressing Tumors
A Phase 1 study, sponsored by MacroGenics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT02628535 is a Phase 1 study that was terminated before completion, run by MacroGenics. The registered enrollment target is 67 participants.
The verdict
NCT02628535, a Phase 1 study, was terminated before completion, sponsored by MacroGenics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.
Interventions
- BIOLOGICAL MGD009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-11-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02628535
The ClinicalTrials.gov registry entry for NCT02628535 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MGD009 is the first listed.
NCT02628535 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02628535 about?
NCT02628535 is a clinical study titled "Safety Study of MGD009 in B7-H3-expressing Tumors". The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacod...
What is the current status of trial NCT02628535?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2015-09. Estimated completion is 2019-11-25.
What interventions are being tested in trial NCT02628535?
The interventions under investigation include: MGD009 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02628535?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.